Factors involved in maintaining Karnofsky Performance Status (≥ 50%) in glioblastoma, IDH-wildtype patients treated with temozolomide and radiotherapy.
Ohba S, Teranishi T, Matsumura K, Kumon M, Kojima D, Fujiwara E, Nakao K, Kuwahara K, Murayama K, Pareira ES, Yamada S, Joko M, Nakae S, Muto J, Nishiyama Y, Adachi K, Sasaki H, Abe M, Hasegawa M, Hirose Y.
Ohba S, et al. Among authors: hasegawa m.
Sci Rep. 2025 Jan 11;15(1):1750. doi: 10.1038/s41598-025-85339-x.
Sci Rep. 2025.
PMID: 39799218